JP5926198B2 - カバノキアレルギーに対するワクチン用ペプチド - Google Patents

カバノキアレルギーに対するワクチン用ペプチド Download PDF

Info

Publication number
JP5926198B2
JP5926198B2 JP2012553390A JP2012553390A JP5926198B2 JP 5926198 B2 JP5926198 B2 JP 5926198B2 JP 2012553390 A JP2012553390 A JP 2012553390A JP 2012553390 A JP2012553390 A JP 2012553390A JP 5926198 B2 JP5926198 B2 JP 5926198B2
Authority
JP
Japan
Prior art keywords
seq
polypeptide
variant
peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012553390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013519717A5 (cg-RX-API-DMAC7.html
JP2013519717A (ja
Inventor
ハフナー、ロデリック、ピーター
レイドラー、ポール
レイトン、ガイ
ラルシェ、マーク
Original Assignee
サーカッシア リミテッド
サーカッシア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーカッシア リミテッド, サーカッシア リミテッド filed Critical サーカッシア リミテッド
Publication of JP2013519717A publication Critical patent/JP2013519717A/ja
Publication of JP2013519717A5 publication Critical patent/JP2013519717A5/ja
Application granted granted Critical
Publication of JP5926198B2 publication Critical patent/JP5926198B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
JP2012553390A 2010-02-15 2011-02-15 カバノキアレルギーに対するワクチン用ペプチド Expired - Fee Related JP5926198B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1002559.1 2010-02-15
GBGB1002559.1A GB201002559D0 (en) 2010-02-15 2010-02-15 Birch peptides for vaccine
PCT/GB2011/000206 WO2011098778A2 (en) 2010-02-15 2011-02-15 Peptides for vaccines against birch allergy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016042511A Division JP2016166194A (ja) 2010-02-15 2016-03-04 カバノキアレルギーに対するワクチン用ペプチド

Publications (3)

Publication Number Publication Date
JP2013519717A JP2013519717A (ja) 2013-05-30
JP2013519717A5 JP2013519717A5 (cg-RX-API-DMAC7.html) 2014-04-03
JP5926198B2 true JP5926198B2 (ja) 2016-05-25

Family

ID=42110757

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012553390A Expired - Fee Related JP5926198B2 (ja) 2010-02-15 2011-02-15 カバノキアレルギーに対するワクチン用ペプチド
JP2016042511A Pending JP2016166194A (ja) 2010-02-15 2016-03-04 カバノキアレルギーに対するワクチン用ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016042511A Pending JP2016166194A (ja) 2010-02-15 2016-03-04 カバノキアレルギーに対するワクチン用ペプチド

Country Status (20)

Country Link
US (2) US9017689B2 (cg-RX-API-DMAC7.html)
EP (2) EP3056213A1 (cg-RX-API-DMAC7.html)
JP (2) JP5926198B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120120965A (cg-RX-API-DMAC7.html)
CN (1) CN102762225B (cg-RX-API-DMAC7.html)
AU (1) AU2011214104B2 (cg-RX-API-DMAC7.html)
CA (2) CA2789353A1 (cg-RX-API-DMAC7.html)
DK (1) DK2536429T3 (cg-RX-API-DMAC7.html)
EA (1) EA201290792A1 (cg-RX-API-DMAC7.html)
ES (1) ES2573651T3 (cg-RX-API-DMAC7.html)
GB (2) GB201002559D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20160481T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029138T2 (cg-RX-API-DMAC7.html)
IL (1) IL221196A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012009431A (cg-RX-API-DMAC7.html)
NZ (1) NZ602380A (cg-RX-API-DMAC7.html)
PL (1) PL2536429T3 (cg-RX-API-DMAC7.html)
SG (1) SG183198A1 (cg-RX-API-DMAC7.html)
SI (1) SI2536429T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011098778A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
WO2013119853A1 (en) * 2012-02-07 2013-08-15 La Jolla Institute For Allergy And Immunology Epitopes from allergen proteins and methods and uses for immune response modulation
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201211586D0 (en) * 2012-06-29 2012-08-15 Circassia Ltd Japanese cedar peptides for preventing or treating allergy
US20150088644A1 (en) 2013-09-23 2015-03-26 Facebook, Inc., a Delaware corporation Predicting User Interactions With Objects Associated With Advertisements On An Online System
CN106699584B (zh) * 2016-12-30 2018-06-26 南京农业大学 一种利用花粉作为天然催化剂制备的γ-氨基丁酸及其制备方法和应用
IL270894B2 (en) 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
CN110175468B (zh) * 2019-05-05 2020-12-01 浙江工业大学 一种保留分布特征的姓名脱敏方法
CN115633666B (zh) * 2021-07-19 2025-11-18 四川大学华西医院 人源化双致敏动物模型和系统性过敏动物模型的构建方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
ES2244708T3 (es) 2002-09-27 2005-12-16 Biomay Produktions- Und Handels- Aktiengesellschaft Vacunas hipoalergenicas contra la alergia basadas en el alergeno phl p 7 de polen de cola de zorro.
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
US20110038881A1 (en) 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine

Also Published As

Publication number Publication date
CN102762225A (zh) 2012-10-31
SI2536429T1 (sl) 2016-08-31
GB2481475A (en) 2011-12-28
AU2011214104A1 (en) 2012-09-06
EP2536429A2 (en) 2012-12-26
HK1165700A1 (en) 2012-10-12
CN102762225B (zh) 2015-05-13
EA201290792A1 (ru) 2013-03-29
WO2011098778A3 (en) 2011-12-15
CA2789353A1 (en) 2011-08-18
GB201102657D0 (en) 2011-03-30
KR20120120965A (ko) 2012-11-02
AU2011214104B2 (en) 2015-05-28
HUE029138T2 (hu) 2017-02-28
GB2481475B (en) 2012-09-19
US9017689B2 (en) 2015-04-28
US20130243798A1 (en) 2013-09-19
MX2012009431A (es) 2012-09-12
NZ602380A (en) 2014-10-31
SG183198A1 (en) 2012-09-27
EP2536429B1 (en) 2016-02-10
ES2573651T3 (es) 2016-06-09
IL221196A0 (en) 2012-10-31
DK2536429T3 (en) 2016-05-23
WO2011098778A2 (en) 2011-08-18
GB201002559D0 (en) 2010-03-31
HRP20160481T1 (hr) 2016-06-03
US20150196635A1 (en) 2015-07-16
PL2536429T3 (pl) 2016-09-30
WO2011098778A8 (en) 2012-09-27
EP3056213A1 (en) 2016-08-17
CA3139588A1 (en) 2011-08-18
JP2016166194A (ja) 2016-09-15
JP2013519717A (ja) 2013-05-30

Similar Documents

Publication Publication Date Title
JP6040207B2 (ja) アレルゲンに対する脱感作のためのペプチド
JP2016166194A (ja) カバノキアレルギーに対するワクチン用ペプチド
JP6215252B2 (ja) ワクチン用ペプチド
AU2013202362B2 (en) Grass Peptides for Vaccine
HK1197371A (en) Grass peptides for vaccine
HK1164700B (en) Peptides for desensibilization against allergens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160421

R150 Certificate of patent or registration of utility model

Ref document number: 5926198

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees